Accelerated ART Initiation for PWHIV Who Are Out of Care

NCT ID: NCT06374758

Last Updated: 2025-04-20

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-29
• Study Completion Date: 2026-11-01

Brief Summary

The main purpose of the study is to evaluate the effectiveness, of the ACCELERATE model of care to achieve HIV viral suppression at Week 24. The study will also assess the acceptability, appropriateness, feasibility, and sustainability of the ACCELERATE model of care. The ACCELERATE model combines a standardized method for outreach, the use of telehealth for rapid access to an HIV care provider, a simplified pre-approved HIV regimen, a free 30-day medication starter supply, and re-linkage to medical care.

Detailed Description

This is a multisite prospective hybrid (effectiveness-implementation) type 2 design, single-arm, mixed-methods study of a simplified accelerated ART initiation protocol for People with HIV who are out of care.

The investigators will assess the effectiveness of achieving HIV viral suppression defined as HIV RNA < 200 copies/mL at week 24 with B/F/TAF (Biktarvy) as a rapid start for PWH who are out of care.

The investigators will also study the acceptability, feasibility, and sustainability of an innovative model of care that combines a standardized method for outreach, the use of telehealth for rapid access to an HIV care provider, a simplified pre-approved ART regimen, a mailed free starter, and re-linkage to care As an implementation science study, the investigators will explore the methods and factors influencing the successful integration of evidence-based practices across diverse settings.

This study will also ask the staff implementing the ACCELERATE approach about its ease of use, feasibility, compliance, and possible obstacles to its application.

Conditions

HIV Infections; ART; Noncompliance, Patient

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: NONE

Study Groups

Accelerate Model of Care

Contact is established by the study team

The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact

At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study

The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.

B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.

A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.

Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider.

Group Type: EXPERIMENTAL

The Accelerate model of care

Intervention Type: OTHER

Contact is established by the study team

The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact

At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study

The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.

B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.

A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.

Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider.

bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg

Intervention Type: DRUG

Same as above, it is the same intervetion

Interventions

The Accelerate model of care

Contact is established by the study team

The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact

At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study

The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.

B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.

A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.

Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider.

Intervention Type: OTHER

bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg

Same as above, it is the same intervetion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. 18 years or older at the time of obtaining the informed consent

2. Speaks English

3. Able to give consent which includes the ability to understand and comply with study requirements and instructions as judged by clinic or study staff

4. HIV-1 infection as documented by positive HIV test (positive laboratory HIV 1/2 Antibody differentiation assay or detectable HIV -1 RNA)

5. Out of care, defined as not had a medical visit with an HIV care provider with prescribing privileges for ≥6 months AND not receiving ART for ≥1 month (by self-report)

1. 18 years or older at the time of obtaining the informed consent

2. HIV care providers, case managers, pharmacists, or administrators involved in administrative or clinical aspects of the intervention at participating sites

3. Understand the long-term commitment to the study and be willing to participate

4. Have adequate resources to complete assessments for the duration of the study

Exclusion Criteria

1. Biktarvy (B/F/TAF) contraindicated or not recommended

1. Known history of chronic kidney disease (creatinine clearance <30 mL/min) using Cockcroft-Gault formula AND not on chronic dialysis

2. Known history of allergy to B/F/TAF components

3. Known history of intermediate-high level resistance to B/F/TAF components (score ≥30 on Stanford HIV Drug Resistance Algorithm) in the available medical record (not having a prior genotype or having M184V/I mutation is NOT an exclusion criterion)

4. Concomitant use of contraindicated medications: using drug interaction database either Lexicomp® Drug Interactions (category X Avoid combination) or Liverpool HIV Interactions Checker (category Do not Co-administer) or study drug label (USPI) as reference for list of contraindicated meds.

5. Pregnant (by self-report) or planning to become pregnant while enrolled in the study

2. HIV-2 infection

3. PLWH who are breastfeeding and are not on ART or taking ART without virologic suppression since breastfeeding will not be recommended.

4. Active opportunistic infections that would require a delay of ART as judged by the HIV care provider and based on current Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: such as cryptococcal and Tuberculous meningitis, and CMV retinitis.16

5. Not residing in the state of Missouri at the time of the study or planning to relocate during the study period

6. Incarcerated at the time of the study enrollment.

1) Moving practice location or job relocation within 1 year

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Gilead Sciences

INDUSTRY

Sponsor Role: collaborator

University of Missouri-Columbia

OTHER

Sponsor Role: lead

Responsible Party

Dima Dandachi

Assistant Professor, Medical Director of HIV treatment and prevention, Columbia/Boone County Health and Human Services

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Dima Dandachi, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

University of Missouri-Columbia

Locations

University of Missouri-Columbia

Columbia, Missouri, United States

Site Status: RECRUITING

KC Care Health Center

Kansas City, Missouri, United States

Site Status: RECRUITING

AIDS Project of the Ozarks

Springfield, Missouri, United States

Site Status: RECRUITING

NOVUS Health

St Louis, Missouri, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Dima Dandachi, MD, MPH

Role: CONTACT

dandachid@health.missouri.edu

(573) 882-7746

Hilal Abdessamad, MD

Role: CONTACT

hilal.abdessamad@health.missouri.edu

5735303333

Facility Contacts

Dima Dandachi, MD

Role: primary

dandachid@health.missouri.edu

573-884-8728

Blair Thedinger, MD

Role: primary

blairt@kccare.org

816-777-2770

Stephen Adams, MD

Role: primary

stephen.adams@apo-ozarks.org

417-881-1300

Mark Scheperle, MD

Role: primary

Mark@novushealthstl.org

314-575-3838

Other Identifiers

MU-2096449

Identifier Type: -

Identifier Source: org_study_id